Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 1;116(9):2258-65.
doi: 10.1002/cncr.25089.

Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)

Veridiana Pires de Camargo  1 , Mary L Keohan, David R D'Adamo, Cristina R Antonescu, Murray F Brennan, Samuel Singer, Linda S Ahn, Robert G Maki
Affiliations

Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)

Veridiana Pires de Camargo et al. Cancer. .

Abstract

Background: In the current study, the authors examined the outcomes of patients with desmoid tumors who received systemic therapy at a single institution to provide a basis for the examination of newer agents.

Methods: Records of patients with desmoid tumors who were treated with chemotherapy at the study institution were reviewed. The activity of nonsteroidal anti-inflammatory drugs was not addressed. Patients without measurable disease and those receiving therapy could not be documented, and those receiving prophylactic therapy were excluded.

Results: A total of 68 patients received 157 lines of therapy. At the time of last follow-up, 9 patients had died, 7 of progressive disease. The cohort was 62% female, with a median age of 32.5 years. Approximately 32% of the patients had Gardner syndrome. The median follow-up was 63 months, and patients received a median of 2 lines of therapy. An intra-abdominal primary tumor location was the most common (44%). The greatest Response Evaluation Criteria in Solid Tumors (RECIST) response rate was observed with anthracyclines and hormonal therapy and the lowest response was noted with single-agent dacarbazine/temozolomide or tyrosine kinase inhibitors, principally imatinib. On multivariate analysis, macroscopic nodular morphology and the presence of Gardner syndrome were the only tumor factors found to be associated with a greater time to disease progression.

Conclusions: Compared with other agents, antiestrogens and anthracycline-containing regimens appear to be associated with a higher radiological response rate against desmoid tumors. Systemic therapy can be successful in patients with desmoid tumors, and is a viable option in lieu of morbid or disabling surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Best RECIST response of therapeutics used to treat desmoid tumors. (A) Anthracycline-containing regimens; (B) Tyrosine kinase inhibitors; (C) Vinca-containing combinations; (D) Hormonal therapy. An asterisk indicates a RECIST partial response.
Figure 1
Figure 1
Best RECIST response of therapeutics used to treat desmoid tumors. (A) Anthracycline-containing regimens; (B) Tyrosine kinase inhibitors; (C) Vinca-containing combinations; (D) Hormonal therapy. An asterisk indicates a RECIST partial response.
Figure 1
Figure 1
Best RECIST response of therapeutics used to treat desmoid tumors. (A) Anthracycline-containing regimens; (B) Tyrosine kinase inhibitors; (C) Vinca-containing combinations; (D) Hormonal therapy. An asterisk indicates a RECIST partial response.
Figure 2
Figure 2
Progression free survival (RECIST) by type of systemic treatment
Figure 3
Figure 3
Overall survival and after diagnosis of desmoid tumor in this patient cohort for all patients (A) and by presence or absence of Gardner syndrome (B).
Figure 3
Figure 3
Overall survival and after diagnosis of desmoid tumor in this patient cohort for all patients (A) and by presence or absence of Gardner syndrome (B).
See this image and copyright information in PMC

References

    1. Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol. 1997;6(2):98–101. - PubMed
    1. Lewis JJ, Boland PJ, Leung DH, Woodruff JM, Brennan MF. The enigma of desmoid tumors. Ann Surg. 1999;229(6):866–72. - PMC - PubMed
    1. Hosalkar HS, Torbert JT, Fox EJ, Delaney TF, Aboulafia AJ, Lackman RD. Musculoskeletal desmoid tumors. J Am Acad Orthop Surg. 2008;16(4):188–98. - PubMed
    1. Nieuwenhuis MH, De Vos Tot Nederveen Cappel W, Botma A, Nagengast FM, Kleibeuker JH, Mathus-Vliegen EM, et al. Desmoid tumors in a dutch cohort of patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2008;6(2):215–9. - PubMed
    1. Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol. 2003;21(9):1698–707. - PubMed

Publication types

Substances